Apotex launches Apo-Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
May 14, 2026Toronto, ON - May 14, 2026 – Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based global health company, today announced the commercial launch of Apo-Semaglutide Injection™ – a generic equivalent of Ozempic®. With initial inventory now available and shipping to wholesalers, Apo-Semaglutide Injection™ will be on pharmacy shelves across Canada within the coming weeks, giving patients and their healthcare providers access to high-quality, affordable alternatives aligned to all available brand-equivalent formats.
Apo-Semaglutide Injection is approved in 2 mg and 4 mg prefilled pen formats, providing:
- 0.25 mg or 0.5 mg doses (2 mg pen; 0.68 mg/mL)
- 1 mg doses (4 mg pen; 1.34 mg/mL)
Apo-Semaglutide Injection™ is administered using a prefilled pen with instructions for use consistent with brand-name semaglutide, supporting familiarity for patients and health care professionals, facilitating a smooth transition.1
In Canada, Apo-Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise.2
"The launch of Apo-Semaglutide Injection reflects our Canadian roots and our dedication to making important treatment options more accessible to people across Canada,"" said Martin Arès, President, Apotex Canada. "With product now available, we are proud to offer a high-quality, affordable option that supports patients, prescribers, and contributes to a strong and reliable healthcare system for Canadians."
Developed in partnership with Orbicular Pharmaceutical Technologies, Apo-Semaglutide Injection underwent Health Canada's standard regulatory review for peptide medicines.
For more than five decades, Apotex has played a meaningful role in Canada's healthcare landscape. By providing high-quality, affordable medicines, the Company helps generate meaningful savings for Canadians and supports broader access to treatment options nationwide.
Healthcare professionals should consult the complete Product Monograph for detailed information on warnings, precautions, adverse reactions, and patient monitoring requirements.
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Learn more at www.apotex.com.
1Apotex data on file
2Product Monograph: https://pdf.hres.ca/dpd_pm/00084514.PDF
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").